Jean Franchi serves as the Chief Financial Officer at Disc Medicine Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for liver diseases and erythropoietic disorders. With over 25 years of experience in finance within the biotechnology and pharmaceutical industries, Franchi brings a proven track record of driving financial strategy and operational excellence in high-growth environments. She joined Disc Medicine in 2023, overseeing all financial operations, including capital raising, investor relations, and strategic planning to support the company's pipeline advancement. Prior to Disc Medicine, Franchi was CFO at Korro Bio from 2021 to 2023, where she led the company's initial public offering and secured significant venture financing. Her earlier roles include Senior Vice President of Finance at bluebird bio, where she managed financial planning during pivotal clinical and commercial milestones, and various finance leadership positions at Alnylam Pharmaceuticals and Genzyme Corporation. Franchi's expertise spans IPOs, mergers and acquisitions, and navigating complex regulatory landscapes, earning her recognition for optimizing capital structures in resource-constrained biotech settings. At Disc Medicine, Franchi plays a critical role in fueling the company's growth, particularly as it advances its lead candidate, DISC-0974, through Phase 2 trials for polycythemia vera and other hematologic conditions. Her strategic vision has positioned the company to attract top-tier investors and partnerships, ensuring sustainable development of innovative therapies aimed at addressing unmet medical needs.